Appia Bio
David Moskowitz has worked at 8VC since 2016, initially as an Intern, then as a Consultant, Senior Associate, and Principal. In 2021, they became a Board Director for hC Bioscience, Inc., Cartography Biosciences, and Appia Bio. Additionally, they are a Co-founding investor and CEO for 8VC NewCo, Co-founding investor and Board Director for Nuanced Health, Board Observer for Unlearn.AI, Mantra Bio, BigHat Biosciences, and Sonoma Biotherapeutics.
David Moskowitz completed a Sc.B. in Computational Biology from Brown University between 2005 and 2009. David then attended Stanford University for a M.S. in Statistics from 2014 to 2016, followed by a Ph.D. in Biomedical Informatics from 2012 to 2017.
This person is not in any teams
This person is not in any offices
Appia Bio
Appia Bio is an early-stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).